INTENSITY THERAPEUTICS INC
INTS · NASDAQ
Updated at 2026-10-13 11:36:21
- Today's High
- --
- Today’s Low
- --
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $3.70
- Previous Close
- $3.31
- Volume
- 41.99K
- Market Cap
- $10.8M
- P/E Ratio
- --
- EPS
- $-4.93
Previous Day Range
52-Week Range
Company Overview
- Sector
- HEALTHCARE
- Industry
- Biotechnology
- Sub-industry
- BIOTECHNOLOGY
- Headquarters
- 1 ENTERPRISE DRIVE, SHELTON, CT, UNITED STATES, 06484-4779
- Country
- US
- Listing Date
- 2023-06-30
- Fiscal Year End
- December
- Shares Outstanding
- 2.7M
- CIK
- 0001567264
Intensity Therapeutics, Inc. is a pioneering biotechnology firm committed to revolutionizing cancer treatment through cutting-edge drug delivery systems. By focusing on enhancing the efficacy of immuno-oncology therapies and reducing systemic side effects, the company addresses critical unmet needs in the oncology market. With a robust research and development pipeline, Intensity Therapeutics aims to advance targeted therapies that empower the immune system to fight cancer more effectively, positioning itself as a leader in improving patient outcomes within a complex and rapidly evolving healthcare landscape.
Financial Metrics
Revenue
2026-06-30
$0
2026-03-31
$0
2025-12-31
-$26K
2025-09-30
$0
Operating Expenses
2026-06-30
$3.08M
2026-03-31
$2.52M
2025-12-31
$3.14M
2025-09-30
$2.73M
Net Income
2026-06-30
-$3M
2026-03-31
-$2.43M
2025-12-31
-$3.05M
2025-09-30
-$2.67M
Net Profit Margin
2026-06-30
--
2026-03-31
--
2025-12-31
11.73K%
2025-09-30
--
Earnings Per Share
2026-06-30
$-1.11
2026-03-31
$-0.96
2025-12-31
$-1.20
2025-09-30
$-1.50
Earnings Before Interest, Taxes, Depreciation, and Amortization
2026-06-30
-$3.08M
2026-03-31
-$2.43M
2025-12-31
-$3.04M
2025-09-30
-$2.66M
Effective Tax Rate
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| Item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$26K | $0 |
| Operating Expenses | $3.08M | $2.52M | $3.14M | $2.73M |
| Net Income | -$3M | -$2.43M | -$3.05M | -$2.67M |
| Net Profit Margin | -- | -- | 11.73K% | -- |
| Earnings Per Share | $-1.11 | $-0.96 | $-1.20 | $-1.50 |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$3.08M | -$2.43M | -$3.04M | -$2.66M |
| Effective Tax Rate | -- | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.